Adele M. Gulfo - 07 Jan 2026 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role: Director
Signature: /s/ Louise Kooij by Power of Attorney from Adele Gulfo
Issuer symbol: NAMS
Transactions as of: 07 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Jan 2026, 19:34:36 UTC
Previous filing: 05 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gulfo Adele M.	Director	C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS	/s/ Louise Kooij by Power of Attorney from Adele Gulfo	09 Jan 2026	0001647102

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NAMS	Ordinary Shares	Award		+3,400	+31%		14,260	07 Jan 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NAMS	Option (right to buy)	Award	$0	+15,300		$0.000000	15,300	07 Jan 2026	Ordinary Shares	15,300	$35.45	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
F2	Each RSU was granted on January 7, 2026 for no consideration.
F3	All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.